Revolution Medicines Jumps 12% as New Data Strengthens Daraxonrasib Case

What happened

Revolution Medicines shares rose 12% in premarket trading after new clinical data reinforced the potential of its lead candidate daraxonrasib. The data adds to early survival signals seen in pancreatic cancer patients, supporting the drug's Breakthrough Therapy Designation. However, the stock still trades near $98, implying an enterprise value of ~$19 billion with no approved products or revenue. The company burns over $1 billion annually, and pivotal Phase 3 results from the RASolute 302 trial remain a key binary event expected in 2026. While the news provides a short-term sentiment lift, it does not alter the fundamental risk that the drug's efficacy must be confirmed in a randomized setting.

Implication

While the data is encouraging, the valuation leaves no room for error; a miss in upcoming Phase 3 reads could lead to severe downside. Investors should wait for a pullback or clearer pivotal data before adding exposure. The master report's base case of $90 and bear case of $60 suggest limited upside from current levels.

Thesis delta

The fresh data provides a marginal positive signal but does not change the core thesis that RVMD is overvalued relative to near-term catalysts and cash burn. The probability-weighted fair value remains below $100, and the favorable data does not justify the current premium. We maintain a cautious stance.